GLP-1 receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-05. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual GIP/GLP-1 receptor agonist |
| Amino acid count | 39 | Contains non-natural residues |
| Modification | C20 fatty diacid | Attached via linker; promotes albumin binding |
| Half-life | Approximately 5 days | Supports once-weekly dosing |
| Primary route | Subcutaneous injection | Not for intravenous use |
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
Regulatory and quality discussions place the peptide within established guidance for synthetic peptides and biologics. Forced degradation studies, in which samples are exposed to heat, acid, base, peroxide, and light, identify likely degradation products and validate the selectivity of analytical methods. Reference standards allow comparison across laboratories and production batches. Purity specifications reported in the literature usually combine chromatographic purity with mass confirmation. Which impurity thresholds are meaningful for long-term behavior is still debated, and no single universal specification has been adopted across all jurisdictions.
Routine characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity assessment, usually with ultraviolet detection near 214 nanometers. Intact mass measurement by liquid chromatography coupled to mass spectrometry confirms molecular identity against a theoretical value. Sequence-level confirmation uses enzymatic digestion followed by tandem mass spectrometry, an approach known as peptide mapping. Amino acid analysis gives an independent check on composition. Circular dichroism spectra are used to estimate helical content in aqueous buffer.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
The molecule is a synthetic 39-amino-acid peptide whose backbone derives from the sequence of human glucose-dependent insulinotropic polypeptide, with several substitutions that raise metabolic stability and shift receptor preference. A C20 fatty diacid is attached through a short linker to a lysine side chain, a modification that increases binding to serum albumin. The reported monoisotopic mass is approximately 4813 Da. Near neutral pH the peptide carries a net negative charge, and the lipid tail makes the molecule markedly more hydrophobic than the unmodified parent sequence.
In July 2025, Karoline Leavitt, the White House press secretary, stated that Trump had been diagnosed with chronic venous insufficiency. Trump's physician, Barbabella, wrote in a statement that bruising on Trump's right hand was attributed to his use of aspirin and frequent hand-shaking. It was later noted, however, that vascular tests confirmed that Trump in fact had swelling in his legs at the time of his diagnosis. Large bruises continued to appear on Trump's hands in August through December of 2025 and in 2026. On August 27, 2025, Vice President JD Vance stated that he was ready to become president; this led to speculation that Trump was seriously ill or dead. That day, he was seen leaving for golf, but a photo which Trump shared of himself on August 31 was determined to have potentially been taken on August 23, fueling further speculation of continuing health concerns. Increased discussion about his mental health occurred in August. A photograph of Trump leaving the White House on September 1 confirmed he was still alive, but led to more speculation about his health due to seeming changes in his appearance. Theories alleging that Trump suffered an ischemic stroke grew following the photos' release; Trump disputed suggestions that he suffered ill health, asserting that he "never felt better in [his] life" in an all-caps Truth Social post. On September 11, during a 9/11 commemoration at the Pentagon, the right side of Trump's face was said to droop down heavily, once again sparking concerns of a stroke.
== Journal of Wound Management == The Journal of Wound Management is the official journal of the European Wound Management Association (EWMA). Issues are published in January, May and October. EWMA Journal is CINAHL indexed and provides peer-reviewed original scientific articles, reviews, clinical information, and information about development in wound healing and management across Europe. The Journal also functions as a communication tool between EWMA, its members and the EWMA cooperating Organisations. The Journal is freely available online under terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) which means that anybody can copy, redistribute in any medium or format, adapt, remix, transform and make indicated changes with appropriate credit. It is prohibited to use the articles for commercial purposes. It is distributed to EWMA members and to members of national wound healing organisations in Europe, as well as to a wider audience via the internet. As a result, each issue of the EWMA Journal is distributed to 12-13,000 nurses, doctors and other health care professionals who have a special interest in wound care.
The Revolt, written by Menachem Begin before he became Prime Minister, tells the story of the Lehi (referred to by their translated name's acronym, F.F.I. "Freedom Fighters of Israel" in early English editions) and Begin's own Irgun fighters during the Jewish insurgency in Palestine. The Revolt influenced groups from a wide variety of ideologies. Some of these groups began to use suicide attacks in the 1990s. The book was allegedly found Osama bin Laden's al-Qaeda organization. Begin praised his militants' willingness to die, "These two wonderful young men greeted the sentence with the singing of Hatikvah". The "two wonderful young men" were the two who blew themselves up in 1947, he described their deaths, "even before they put on their red uniforms. They too held their heads high when they faced their judges… But they did not reach the gallows. They too sang on the threshold of death — a song of faith in God: 'Lord of the world who reigned before creation'. But their song ended with a great explosion which shattered the silence of the prison in occupied Jerusalem". In 1977 the author became prime minister, after previously being in opposition. Historical militants featured prominently in his political speeches. He praised the actions of his militants during the insurgency in Palestine in the 1940s, including the leader of the cell who bombed the King David Hotel (killing 91 people and 1 terrorist). His favourites were, again, the two young militants who blew themselves up in Jerusalem prison in 1947.
Sources: en.wikipedia.org
=== Synthetic enzymes === Regardless of the details, an outstanding issue is that the physiological route of NAADP synthesis has still not been unequivocally identified — neither the reaction(s) nor the enzyme(s). Clearly, it is theoretically possible there may be multiple routes of synthesis, but this would be unprecedented in the second messenger world. To date, the most favoured hypothesis is the so-called base-exchange reaction (nicotinic acid + NADP → NAADP + nicotinamide; catalyzed by ADP-ribosyl cyclases) which are a family of enzymes that include CD38 and CD157 in mammals (and orthologs in sea urchin and Aplysia ovotestis). These were first discovered as the synthetic enzymes for cADPR but later revealed to be multifunctional, promiscuous enzymes that can also produce NAADP. Certainly NAADP production can occur in vitro but whether it occurs in vivo is another question (because genetic knockout or knock-down of ADP-ribosyl cyclases has no effect on NAADP production in some cell types), and there may be other routes which require different substrates and enzymes. The SARM1 enzyme also catalyzes the formation of NAADP from NAD+. The first chemical synthesis of NAADP was achieved in 2004 using a chemoenzymatic approach: a total chemical synthesis of NADP and then conversion of this to NAADP enzymatically.
Ammonium sulfate precipitation is one of the most commonly used methods for large and laboratory scale protein purification and fractionation that can be used to separate proteins by altering their solubility in the presence of a high salt concentration.
In 1985, the International Union of Pure and Applied Chemistry (IUPAC) and the International Union of Pure and Applied Physics (IUPAP) formed a Transfermium Working Group (TWG) to assess discoveries and establish final names for the controversial elements. The party held meetings with delegates from the three competing institutes; in 1990, they established criteria on recognition of an element, and in 1991, they finished the work on assessing discoveries and disbanded. These results were published in 1993. According to the report, the first definitely successful experiment was the April 1970 LBL experiment, closely followed by the June 1970 JINR experiment, so credit for the discovery of the element should be shared between the two teams. LBL said that the input from JINR was overrated in the review. They claimed JINR was only able to unambiguously demonstrate the synthesis of element 105 a year after they did. JINR and GSI endorsed the report. In 1994, IUPAC published a recommendation on naming the disputed elements. For element 105, they proposed joliotium (Jl) after the French physicist Frédéric Joliot-Curie, a contributor to the development of nuclear physics and chemistry; this name was originally proposed by the Soviet team for element 102, which by then had long been called nobelium. This recommendation was criticized by the American scientists for several reasons. Firstly, their suggestions were scrambled: the names rutherfordium and hahnium, originally suggested by Berkeley for elements 104 and 105, were respectively reassigned to elements 106 and 108.
Hours after the capture, the United States attorney general Pam Bondi announced that Maduro and Flores had been indicted in the Southern District of New York on charges related to "narcoterrorism". The indictment listed the charges as narco-terrorism conspiracy, cocaine importation conspiracy, possession of machine guns and destructive devices, and conspiracy to possess machine guns and destructive devices. The amended indictment did not refer to the Cartel of the Suns as an organized group as previously alleged by the US, but instead as a corrupt patronage system, which aligns with experts' descriptions of its operations. Maduro and his wife were arraigned in a Manhattan federal court on 5 January 2026. Before pleading, Maduro said: "I am the president of Venezuela, I consider myself a prisoner of war. I was captured at my home in Caracas." Both pleaded not guilty to numerous drug trafficking charges. US District Judge Alvin Hellerstein ordered that Maduro be held at least until a hearing. Originally scheduled for 17 March, the hearing was delayed to 26 March. Maduro and Flores appeared in court for it, then were transferred back to jail in Brooklyn. Maduro is reportedly spending most of his time in prison reading the Bible. He does not have access to newspapers or the internet in prison, but he is allowed to speak by telephone with his family and lawyers for approximately 300 minutes a month, with a maximum of 15 minutes per call. Their trial was scheduled for 1 June 2027.
Sources: en.wikipedia.org
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.
It is given as a subcutaneous injection. Its long half-life supports weekly dosing.
No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。